SCHEDULE 13G/A: Highbridge Capital Management Discloses 7.7% Stake in BioAtla, Inc. via Warrants

Highbridge Capital Management, LLC has filed an amended Schedule 13G, disclosing a 7.7% beneficial ownership stake in BioAtla, Inc., primarily through warrants.

Summary

• Highbridge Capital Management, LLC, an investment adviser, has filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in BioAtla, Inc.
• The filing indicates Highbridge Capital Management, on behalf of its Highbridge Funds, beneficially owns 4,839,579 shares of BioAtla, Inc. Common Stock.
• This ownership represents 7.7% of BioAtla's outstanding Common Stock.
• The reported shares are issuable upon the exercise of warrants directly held by the Highbridge Funds.
• The percentage is calculated based on 58,401,147 shares of Common Stock outstanding as of March 26, 2025, as reported in BioAtla's Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• Highbridge certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of BioAtla.
• Highbridge Tactical Credit Master Fund, L.P., a Highbridge Fund, holds the right to receive dividends or proceeds from the sale of more than 5% of the Common Stock.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing disclosing passive ownership and does not convey a strong positive or negative sentiment regarding the issuer's performance or prospects. It is neutral in tone.

Positives

• Disclosure of significant institutional ownership by Highbridge Capital Management, a reputable investment adviser, may signal confidence in BioAtla.
• The filing confirms the passive nature of the investment, indicating Highbridge is not seeking to influence control of the issuer.

Risks

• The beneficial ownership is primarily through warrants, which introduces potential dilution risk for existing shareholders if exercised, depending on the strike price relative to the market price.
• The value of the stake is subject to market fluctuations of BioAtla's common stock.

Future Outlook

The document is a passive ownership disclosure and does not contain any forward-looking statements or guidance regarding BioAtla, Inc.'s future performance or strategic direction.

Industry Context

This filing is a routine disclosure of institutional ownership and does not provide specific insights into broader industry trends. However, significant institutional stakes in biotechnology companies like BioAtla can sometimes indicate investor interest in the sector's innovation or specific therapeutic areas, though this filing itself does not elaborate on such.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which could be viewed positively as a vote of confidence or raise questions about potential future warrant exercises and dilution.

Key Dates

Keywords

BioAtla Inc., Highbridge Capital Management, Schedule 13G, Beneficial Ownership, Warrants, Common Stock, Investment Adviser, SEC Filing, Institutional Ownership, Biotechnology, Pharmaceuticals